PARAMUS, N.J., July 1, 2025 /PRNewswire/ — NS Pharma, Inc. (NS Pharma) announced today that its parent company, Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), headquartered in Kyoto, Japan, has finalized a strategic partnership with Boston Children’s Hospital (Boston Children’s) (Headquarters: Boston, Massachusetts, United States), to support the research and development of innovative therapies for rare diseases. Nippon Shinyaku and Boston Children’s will leverage their combined expertise in clinical research and pharmaceutical development to bring more treatment options to patients. The agreement was facilitated by the NS Pharma Innovation Research Partnering (IRP) team, located in Cambridge, MA.
“Through our strategic alliance with Boston Children’s Hospital, the NS Group will continue to apply advanced medical technology in the field of rare diseases,” said NS Pharma President Yukiteru Sugiyama. “We are excited about the extensive opportunities for innovation derived from this collaboration and the ability to deliver new therapies to patients suffering from these conditions as soon as possible.”
Under this alliance, Nippon Shinyaku and Boston Children’s will align their focus areas, aiming to inspire and support research proposals focused on rare diseases. Nippon Shinyaku will assess the Boston Children’s proposals and select those of interest for joint research. Proposals may span a range of developmental stages, from early investigations into the biological mechanisms of rare disease, to the identification of possible therapeutic targets, or the generation and validation of new therapeutic entities.
About NS Pharma, Inc.
NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd., headquartered in Paramus, NJ. NS Pharma is a registered trademark of the Nippon Shinyaku Co., Ltd. Nippon Shinyaku is focused on incurable and rare diseases and is currently marketing Viltepso® (nucleic acid drug), a treatment for Duchenne muscular dystrophy developed in-house, in Japan and the United States.
For more information, please visit nspharma.com.
US Media Contact:
media@nspharma.com
SOURCE NS Pharma, Inc.
Dr. Ran Rubinstein discusses how individualized treatment planning determines when fillers, neurotoxins, or collagen-stimulating injectables…
PALO ALTO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the…
TAIZHOU, China, Jan. 30, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the…
Melbourne, Australia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Key Highlights from the Quarter ACCENT Trial…
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX…
Company expects up to six-month review period per FDA guidelines New longer-term clinical data demonstrating…